Apnimed (APMD)
Develops Oxnimbi, an oral therapy under FDA review for obstructive sleep apnea.
$23.00
vs last close−2.51 (−9.84%)
Something off on this page? Send us feedback.
EPSReportedEstimate
———————Sep '26
Reported———————$3.92
Estimate———————−$0.49
Surprise———————+905.5%
RevenueReportedEstimate
———————Sep '26
Reported———————$12.1M
Estimate————————
Surprise————————
History
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2026 | −$0.49 | $3.92 | +905.5% |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | −$0.49 | $3.92 | +905.5% | — | $12.1M | — | −2.5% |